A composition for use in the treatment of cancer, said composition comprising: (a) an AAAPT bioconjugate of Formula 1: A-L-T Formula 1 and (b) an agent selected from a chemotherapeutic agent, an immunotherapeutic agent, a radiation therapy agent, and a radionuclide therapy agent; wherein (a) is selected from the following compounds: (i) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -O(CH 2) f (CH 2 CH 2 O) g (CH 2) h O-, (ii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) e -; (iii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) b CO-; (iv) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -OC(CH 2) a CO-; (v) A is alpha-tocopherol, T is octreotate and L is val-cit-HN(CH 2) e -; (vi) A is human defensin-1 protein, T is human defensin-1 protein, and L is EEEEEP-Cit-GHof-YL; (vii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -O(CH 2) f (CH 2 CH 2 O)g(CH 2) h O-, g is 1000 and h is 2; (viii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) e -, e is 3; and (ix) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) b CO-, b is 3; unless otherwise defined, subscripts 'a', 'b', 'and 'e' independently vary from 1 to 10; unless otherwise defined, subscripts 'f', 'g', and 'h', independently vary from 1-5000; and wherein said chemotherapeutic agent comprises doxorubicin, avastin, epirubicin, paclitaxel, docetaxel, 5-fluorouracil, cyclophosphamide, cisplatin, carboplatin, vinorelbine, capecitabine, liposomal doxorubicin, gemcitabine, ixabepilone, albumin-bound paclitaxel, eribulin, irinotecan, etoposide, vinblastine, tamoxifen, methotrexate, or pemetrexed; said immunotherapeutic agent comprises deactivated viral particles, alemtuzumab, atezolizumab, ipilimumab, ofatumumab, trastuzumab, rituximab, adalimumab, infliximab, etanercpet, or abatacept; said radiation therapy agent is an external beam radiation; and said radionuclide therapy agent comprises 123 I, 125 I, 131 I, 186/188 Re, 111 In, 177 Lu, 153 Sm, 89 Sr, 90 Y, 201 Pb, 32 P, 198 Au, 165 Dy, 80m Br, 67 Cu, or 117 Sn. (a) an AAAPT bioconjugate of Formula 1: A-L-T Formula 1 and (b) an agent selected from a chemotherapeutic agent, an immunotherapeutic agent, a radiation therapy agent, and a radionuclide therapy agent; wherein (a) is selected from the following compounds: (i) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -O(CH 2) f (CH 2 CH 2 O) g (CH 2) h O-, (ii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) e -; (iii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) b CO-; (iv) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -OC(CH 2) a CO-; (v) A is alpha-tocopherol, T is octreotate and L is val-cit-HN(CH 2) e -; (vi) A is human defensin-1 protein, T is human defensin-1 protein, and L is EEEEEP-Cit-GHof-YL; (vii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -O(CH 2) f (CH 2 CH 2 O)g(CH 2) h O-, g is 1000 and h is 2; (viii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) e -, e is 3; and (ix) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) b CO-, b is 3; (i) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -O(CH 2) f (CH 2 CH 2 O) g (CH 2) h O-, (ii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) e -; (iii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) b CO-; (iv) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -OC(CH 2) a CO-; (v) A is alpha-tocopherol, T is octreotate and L is val-cit-HN(CH 2) e -; (vi) A is human defensin-1 protein, T is human defensin-1 protein, and L is EEEEEP-Cit-GHof-YL; (vii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -O(CH 2) f (CH 2 CH 2 O)g(CH 2) h O-, g is 1000 and h is 2; (viii) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) e -, e is 3; and (ix) A is alpha-tocopherol, T is Valine-Citrulline (Val-Cit) and L is -HN(CH 2) b CO-, b is 3; unless otherwise defined, subscripts 'a', 'b', 'and 'e' independently vary from 1 to 10; unless otherwise defined, subscripts 'f', 'g', and 'h', independently vary from 1-5000; and wherein said chemotherapeutic agent comprises doxorubicin, avastin, epirubicin, paclitaxel, docetaxel, 5-fluorouracil, cyclophosphamide, cisplatin, carboplatin, vinorelbine, capecitabine, liposomal doxorubicin, gemcitabine, ixabepilone, albumin-bound paclitaxel, eribulin, irinotecan, etoposide, vinblastine, tamoxifen, methotrexate, or pemetrexed; said immunotherapeutic agent comprises deactivated viral particles, alemtuzumab, atezolizumab, ipilimumab, ofatumumab, trastuzumab, rituximab, adalimumab, infliximab, etanercpet, or abatacept; said radiation therapy agent is an external beam radiation; and said radionuclide therapy agent comprises 123 I, 125 I, 131 I, 186/188 Re, 111 In, 177 Lu, 153 Sm, 89 Sr, 90 Y, 201 Pb, 32 P, 198 Au, 165 Dy, 80m Br, 67 Cu, or 117 Sn. said immunotherapeutic agent comprises deactivated viral particles, alemtuzumab, atezolizumab, ipilimumab, ofatumumab, trastuzumab, rituximab, adalimumab, infliximab, etanercpet, or abatacept; said radiation therapy agent is an external beam radiation; and said radionuclide therapy agent comprises 123 I, 125 I, 131 I, 186/188 Re, 111 In, 177 Lu, 153 Sm, 89 Sr, 90 Y, 201 Pb, 32 P, 198 Au, 165 Dy, 80m Br, 67 Cu, or 117 Sn.